See more : Oriental Consultants Holdings Company Limited (2498.T) Income Statement Analysis – Financial Results
Complete financial analysis of TELA Bio, Inc. (TELA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of TELA Bio, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
- Arcadia Minerals Limited (AM7.AX) Income Statement Analysis – Financial Results
- Novartis India Limited (NOVARTIND.NS) Income Statement Analysis – Financial Results
- Kinea Renda Imobiliária Fundo de Investimento Imobiliário (KNRI11.SA) Income Statement Analysis – Financial Results
- General Electric Company (GE) Income Statement Analysis – Financial Results
- Duke Energy Corporation (DUK-PA) Income Statement Analysis – Financial Results
TELA Bio, Inc. (TELA)
About TELA Bio, Inc.
TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. It provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. The company markets its products through a single direct sales force, principally in the United States. TELA Bio, Inc. was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 58.45M | 41.42M | 29.46M | 18.21M | 15.45M | 8.27M | 4.25M |
| Cost of Revenue | 18.34M | 14.37M | 10.65M | 6.98M | 6.17M | 5.33M | 1.71M |
| Gross Profit | 40.11M | 27.04M | 18.81M | 11.23M | 9.27M | 2.94M | 2.53M |
| Gross Profit Ratio | 68.62% | 65.30% | 63.85% | 61.68% | 60.03% | 35.56% | 59.65% |
| Research & Development | 9.62M | 8.94M | 6.74M | 4.26M | 4.15M | 4.34M | 5.79M |
| General & Administrative | 14.89M | 13.86M | 12.46M | 10.14M | 6.22M | 4.90M | 4.96M |
| Selling & Marketing | 59.68M | 43.25M | 29.06M | 22.11M | 18.06M | 13.65M | 8.71M |
| SG&A | 74.57M | 57.11M | 41.52M | 32.25M | 24.28M | 18.55M | 13.67M |
| Other Expenses | 0.00 | -10.00K | -228.00K | 45.00K | 351.00K | 70.00K | 94.00K |
| Operating Expenses | 84.19M | 66.05M | 48.26M | 36.51M | 28.43M | 22.88M | 19.46M |
| Cost & Expenses | 102.53M | 80.43M | 58.91M | 43.49M | 34.61M | 28.22M | 21.17M |
| Interest Income | 0.00 | 4.05M | 3.60M | 3.56M | 3.61M | 0.00 | 0.00 |
| Interest Expense | 5.22M | 4.05M | 3.60M | 3.56M | 3.61M | 1.80M | 4.56M |
| Depreciation & Amortization | 808.00K | 1.19M | 535.00K | 525.00K | 582.00K | 1.25M | 761.00K |
| EBITDA | -40.63M | -39.06M | -29.14M | -24.71M | -18.23M | -18.04M | -16.02M |
| EBITDA Ratio | -69.51% | -94.20% | -100.73% | -138.53% | -121.79% | -225.09% | -378.54% |
| Operating Income | -44.08M | -39.01M | -29.45M | -25.28M | -19.16M | -17.78M | -16.92M |
| Operating Income Ratio | -75.40% | -94.18% | -99.96% | -138.77% | -124.06% | -214.91% | -398.68% |
| Total Other Income/Expenses | -2.59M | -5.29M | -3.83M | -3.52M | -3.26M | -3.31M | -4.41M |
| Income Before Tax | -46.66M | -44.30M | -33.28M | -28.79M | -22.43M | -21.09M | -21.33M |
| Income Before Tax Ratio | -79.83% | -106.95% | -112.94% | -158.10% | -145.18% | -254.92% | -502.57% |
| Income Tax Expense | 0.00 | 41.00K | 2.83M | 3.08M | 3.38M | -1.51M | 4.65M |
| Net Income | -46.66M | -44.34M | -36.11M | -31.88M | -25.80M | -21.09M | -21.33M |
| Net Income Ratio | -79.83% | -107.05% | -122.56% | -175.03% | -167.05% | -254.92% | -502.57% |
| EPS | -2.04 | -2.73 | -2.49 | -2.46 | -2.26 | -3.25 | -3.29 |
| EPS Diluted | -2.04 | -2.73 | -2.49 | -2.46 | -2.26 | -3.25 | -3.29 |
| Weighted Avg Shares Out | 22.87M | 16.27M | 14.47M | 12.93M | 11.41M | 6.49M | 6.49M |
| Weighted Avg Shares Out (Dil) | 22.87M | 16.27M | 14.47M | 12.93M | 11.41M | 6.49M | 6.49M |
TELA Bio, Inc. (TELA) Reports Q2 Loss, Lags Revenue Estimates
TELA Bio Reports Second Quarter 2023 Financial Results
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
TELA Bio to Announce Second Quarter 2023 Financial Results and Confirms Participation in the Canaccord Genuity 43rd Annual Growth Conference
Strength Seen in TELA Bio, Inc. (TELA): Can Its 11.4% Jump Turn into More Strength?
TELA Bio to Participate in the Jefferies Global Healthcare Conference
TELA Bio, Inc. (TELA) Q1 2023 Earnings Call Transcript
TELA Bio, Inc. (TELA) Reports Q1 Loss, Misses Revenue Estimates
TELA Bio to Announce First Quarter 2023 Financial Results
Why TELA Bio Stock Is Dropping Today - TELA Bio (NASDAQ:TELA)
Source: https://incomestatements.info
Category: Stock Reports